HC Wainwright Issues Optimistic Outlook for TSE:FRX Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Stock analysts at HC Wainwright increased their Q3 2027 earnings per share estimates for shares of Fennec Pharmaceuticals in a report released on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn $0.40 per share for the quarter, up from their previous forecast of $0.34. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2027 earnings at $0.47 EPS.

Fennec Pharmaceuticals Price Performance

FRX opened at C$19.17 on Thursday. The company has a market capitalization of C$676.80 million, a PE ratio of -159.75 and a beta of 3.90. Fennec Pharmaceuticals has a fifty-two week low of C$7.59 and a fifty-two week high of C$19.84. The business has a 50-day moving average of C$15.06 and a 200-day moving average of C$13.15.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, insider Robert Christopher Andrade sold 106,844 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the completion of the sale, the insider directly owned 217,675 shares of the company’s stock, valued at C$3,619,935.25. The trade was a 32.92% decrease in their ownership of the stock. Also, insider Pierre Sayad sold 12,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of C$17.18, for a total transaction of C$206,160.00. Following the transaction, the insider owned 9,519 shares in the company, valued at approximately C$163,536.42. This trade represents a 55.76% decrease in their position. Insiders own 16.20% of the company’s stock.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A hedge fund recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals at the end of the most recent reporting period. 16.86% of the stock is owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.

See Also

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.